<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cyclosporine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00091</strong>&#160; (BIOD00003, BTD00003)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. Cyclosporine is produced as a metabolite by the fungus species Cordyceps militaris. (From Martindale, The Extra Pharmacopoeia, 30th ed).</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00091/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00091/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00091.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00091.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00091.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00091.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00091.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00091">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ciclosporin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN</td></tr><tr><td>CsA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>CyA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cyclosporin A</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Gengraf</td><td>Abbott Labs </td></tr><tr><td>Neoral </td><td>Novartis </td></tr><tr><td>Restasis </td><td>Allergan Inc. </td></tr><tr><td>Sandimmune </td><td>Novartis </td></tr><tr><td>Sangcya</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antirheumatic-agents">Antirheumatic Agents</a></li>
<li><a href="/mesh/dermatologic-agents">Dermatologic Agents</a></li>
<li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li>
<li><a href="/mesh/antifungal-agents">Antifungal Agents</a></li>
<li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>59865-13-3</td></tr><tr><th>Weight</th><td>Average: 1202.6112<br>Monoisotopic: 1201.841368071</td></tr><tr><th>Chemical Formula</th><td>C<sub>62</sub>H<sub>111</sub>N<sub>11</sub>O<sub>12</sub></td></tr><tr><th>InChI Key</th><td>PMATZTZNYRCHOR-IMVLJIQENA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Cyclosporins</td></tr><tr><th>Alternative parents</th><td>Macrolactams; Tertiary Carboxylic Acid Amides; Secondary Alcohols; Secondary Carboxylic Acid Amides; Tertiary Amines; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>macrolactam; tertiary carboxylic acid amide; tertiary amine; secondary alcohol; carboxamide group; secondary carboxylic acid amide; carboxylic acid; polyamine; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the cyclosporins. These are cyclic depsipeptides containing the cyclosporin backbone.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis. </td></tr><tr><th>Pharmacodynamics</th><td>Used in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2.</td></tr><tr><th>Mechanism of action</th><td>Cyclosporine binds to cyclophilin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and interleukin release. In ophthalmic applications, the precise mechanism of action is not known. Cyclosporine emulsion is thought to act as a partial immunomodulator in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.</td></tr><tr><th>Absorption</th><td>The absorption of cyclosporine from the gastrointestinal tract is incomplete and variable. The extent of absorption is dependent on the individual patient, the patient population, and the formulation. The absolute bioavailability of cyclosproine administered as Sandimmune&#174; is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. Compared to an intravenous infusion, the absolute bioavailability of the oral solution is approximately 30% based upon the results in 2 patients. The cyclosporine capsules and oral solution are bioequivalent. The time of peak blood concentrations (Tmax) following oral administration of cyclosporine [modified] ranged from 1.5 - 2.0 hours. </td></tr><tr><th>Volume of distribution</th><td><p>The steady state volume of distribution during intravenous dosing has been reported as 3 to 5 L/kg in solid organ transplant recipients. Cyclosporine is excreted in human milk.</p></td></tr><tr><th>Protein binding</th><td>In the plasma, approximately 90% is bound to proteins, primarily lipoproteins. In blood, the distribution is concentration dependent. Approximately 33% to 47% is in plasma, 4% to 9% in lymphocytes, 5% to 12% in granulocytes, and 41% to 58% in erythrocytes. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, extensively metabolized by the cytochrome P450 3A enzyme system in the liver. It is also metabolized in the gastrointestinal tract and kidney to a lesser degree. The metabolites are significantly less potent than the parent compound. The major metabolites (M1, M9, and M4N) result from oxidation at the 1-beta, 9-gamma, and 4-N-demethylated positions, respectively.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Cyclosporine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00359">Metabolite AM1</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/361">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Elimination is primarily biliary with only 6% of the dose (parent drug and metabolites) excreted in the urine. Only 0.1% of the dose is excreted in the urine as unchanged drug.</td></tr><tr><th>Half life</th><td>Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.</td></tr><tr><th>Clearance</th><td><p>Following intravenous administration, the blood clearance of cyclosporine (assay: <span class="caps">HPLC</span>) is approximately 5 to 7 mL/min/kg in adult recipients of renal or liver allografts. Blood cyclosporine clearance appears to be slightly slower in cardiac transplant patients. The following are clearance parameters (CL/F) for select patient populations:</p>
<ul>
	<li>593 &#177; 204 mL/min [De novo renal transplant patients, 597&#177;174 mg/day]</li>
	<li>492 &#177; 140 mL/min [Stable renal transplant patients, 344&#177;122 mg/day]</li>
	<li>577 &#177; 309 mL/min [De novo liver transplant, 458&#177;190 mg/day]</li>
	<li>613 &#177; 196 mL/min [De novo rheumatoid arthritis, 182&#177;55.6 mg/day]</li>
	<li>723 &#177; 186 mL/min [De novo psoriasis, 189&#177;69.8 mg/day]</li>
	<li>285 &#177; 94 mL/min [Stable Liver Transplant, Age 2 &#8211; 8, Dosed T.I.D 101&#177;25 mg/day]</li>
	<li>378 &#177; 80 mL/min [Stable Liver Transplant, Age 8 &#8211; 15, Dosed B.I.D 188&#177;55 mg/day]</li>
	<li>171 mL/min [Stable liver transplant, Age 3, Dosed B.I.D 120 mg/day]</li>
	<li>328 &#177; 121 mL/min [Stable liver transplant, Age 8 &#8211; 15, Dosed B.I.D 158&#177;55 mg/day]</li>
	<li>418 &#177; 143 mL/min [Stable renal transplant, Age 7 &#8211; 15, Dosed B.I.D 328&#177;83 mg/day]</li>
</ul></td></tr><tr><th>Toxicity</th><td>The oral LD<sub>50</sub> is 2329 mg/kg in mice, 1480 mg/kg in rats, and &gt; 1000 mg/kg in rabbits. The I.V. LD<sub>50</sub> is 148 mg/kg in mice, 104 mg/kg in rats, and 46 mg/kg in rabbits.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytotoxic T-lymphocyte protein 4<br>Gene symbol: CTLA4<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P16410" target="_blank">P16410 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs231775" target="_blank">rs231775 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A Allele</td><td>Gingival overgrowth, periodontal disease</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18021981" target="_blank" title="Kusztal M, Radwan-Oczko M, Koscielska-Kasprzak K, Boratynska M, Patrzalek D, Klinger M: Possible association of CTLA-4 gene polymorphism with cyclosporine-induced gingival overgrowth in kidney transplant recipients. Transplant Proc. 2007 Nov;39(9):2763-5.">18021981 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8727</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6994</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8463</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8685</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5992</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9485</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8628</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8823</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6407</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9265</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6112</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9968</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8948
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9244
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.8788 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9815
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9214
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Apotex inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Pliva inc</li>
<li>Sandoz inc</li>
<li>Abbott laboratories</li>
<li>Novartis pharmaceuticals corp</li>
<li>Allergan inc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Pharmaforce inc</li>
<li>Novex pharma</li>
<li>Watson laboratories inc</li>
<li>Wockhardt eu operations (swiss) ag</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li><a href="http://www.allergan.com">Allergan Inc.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.banpharm.com">Banner Pharmacaps Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li><a href="http://www.draxispharma.com">Draxis Specialty Pharmaceuticals Inc.</a></li>
<li>Eon Labs</li>
<li>Ivax Pharmaceuticals</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.paddocklabs.com">Paddock Labs</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.rpscherer.de">R.P. Scherer GmbH and Co. KG</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li>Sangstat Medical Corp.</li>
<li><a href="http://www.santecchemcorp.com">Santec Chemicals Corp.</a></li>
<li><a href="http://www.swisscaps.com">Swiss Caps Ag</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>25 mg, 50 mg, 100 mg</td></tr><tr><td>Emulsion</td><td>Ophthalmic</td><td>0.05%</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>50 mg/mL</td></tr><tr><td>Solution</td><td>Oral</td><td>100 mg/mL</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00819">Acetazolamide</a></td><td>Acetazolamide may increase the effect and toxicity of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00437">Allopurinol</a></td><td>Allopurinol increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may increase the therapeutic and adverse effects of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01351">Amobarbital</a></td><td>The barbiturate, amobarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00681">Amphotericin B</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>The protease inhibitor, amprenavir, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01352">Aprobarbital</a></td><td>The barbiturate, aprobarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the therapeutic and adverse effects of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00207">Azithromycin</a></td><td>The macrolide, azithromycin, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>Cyclosporine may enhance the nephrotoxic effect of fibric acid derivatives like bezafibrate. Fibric acid derivatives may decrease the serum concentration of cyclosporine. Extra monitoring of renal function and cyclosporine concentrations will likely be required. Adjustment of cyclosporine dose may be necessary.</td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Cyclosporine may increase the effect and toxicity of bosentan.</td></tr><tr><td><a href="/drugs/DB01156">Bupropion</a></td><td>Bupropion may decrease the therapeutic effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>The barbiturate, butabarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>The barbiturate, butalbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01353">Butethal</a></td><td>The barbiturate, butethal, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the therapeutic effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Carvedilol may increase the therapeutic and adverse effects of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00520">Caspofungin</a></td><td>Cyclosporine increases the effect and toxicity of caspofungin</td></tr><tr><td><a href="/drugs/DB00439">Cerivastatin</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Chloramphenicol may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00608">Chloroquine</a></td><td>Chloroquine may increase the therapeutic and adverse effects of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01597">Cilastatin</a></td><td>Imipenem increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00537">Ciprofloxacin</a></td><td>Ciprofloxacin may increase the effect and toxicity of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01190">Clindamycin</a></td><td>Clindamycin may decrease the therapeutic effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Increased toxicity of both drugs</td></tr><tr><td><a href="/drugs/DB01406">Danazol</a></td><td>The androgen, danazol, may increase the effect and toxicity of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00586">Diclofenac</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Cyclosporine may increase the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>The barbiturate, dihydroquinidine barbiturate, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem may increase the effect and toxicity of cyclosporine.</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Cyclosporine is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. </td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenz decreases the levels of cyclosporine</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>The contraceptive increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The hydantoin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00749">Etodolac</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00773">Etoposide</a></td><td>Cyclosporine may increase the therapeutic and adverse effects of etoposide.</td></tr><tr><td><a href="/drugs/DB00973">Ezetimibe</a></td><td>Cyclosporine may increase the therapeutic and adverse effects of ezetimibe.</td></tr><tr><td><a href="/drugs/DB00573">Fenoprofen</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB08874">Fidaxomicin</a></td><td>Cyclosporin is an inhibitor of p-glycoprotein and concomitant therapy will result in a increase in Cmax and AUC of fidaxomicin and its metabolite. </td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the therapeutic and adverse effects of the cyclosporine.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>The antidepressant increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00712">Flurbiprofen</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01095">Fluvastatin</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>The protease inhibitor, fosamprenavir, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00529">Foscarnet</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The hydantoin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00222">Glimepiride</a></td><td>The sulfonylurea, glimepiride, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01067">Glipizide</a></td><td>The sulfonylurea, glipizide, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>The sulfonylurea, glibenclamide, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>Griseofulvin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01354">Heptabarbital</a></td><td>The barbiturate, heptabarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01355">Hexobarbital</a></td><td>The barbiturate, hexobarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB01598">Imipenem</a></td><td>Imipenem increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>The protease inhibitor, indinavir, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The macrolide, josamycin, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>The NSAID, ketoprofen, may increase the serum concentration of cyclosporine. Ketoprofen may also increase the nephrotoxicity of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00939">Meclofenamic acid</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00784">Mefenamic acid</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01042">Melphalan</a></td><td>Melphalan increases toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The hydantoin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>The contraceptive increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00474">Methohexital</a></td><td>The barbiturate, methohexital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>Cyclosporine may increase the effect and toxicity of methotrexate.</td></tr><tr><td><a href="/drugs/DB00422">Methylphenidate</a></td><td>Methylphenidate increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00849">Methylphenobarbital</a></td><td>The barbiturate, methylphenobarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01233">Metoclopramide</a></td><td>Metoclopramide increases serum levels of cyclosporine</td></tr><tr><td><a href="/drugs/DB00745">Modafinil</a></td><td>Modafinil decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00075">Muromonab</a></td><td>Muromonab increases the levels of cyclosporine</td></tr><tr><td><a href="/drugs/DB00461">Nabumetone</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00607">Nafcillin</a></td><td>Nafcillin alters serum levels of cyclosporine</td></tr><tr><td><a href="/drugs/DB00788">Naproxen</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>The antidepressant increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>The protease inhibitor, nelfinavir, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>Nicardipine increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB01115">Nifedipine</a></td><td>Increased risk of gingivitis</td></tr><tr><td><a href="/drugs/DB01059">Norfloxacin</a></td><td>Norfloxacin may increase the effect and toxicity of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00104">Octreotide</a></td><td>Octreotide decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB01083">Orlistat</a></td><td>Orlistat decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00991">Oxaprozin</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00776">Oxcarbazepine</a></td><td>Oxcarbazepine decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>The barbiturate, pentobarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The barbiturate, phenobarbital, may decrease the therapeutic effect of cyclosporine by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The hydantoin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB08860">Pitavastatin</a></td><td>Cyclosporine decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy.</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Increased level of cyclosporine</td></tr><tr><td><a href="/drugs/DB00175">Pravastatin</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The barbiturate, primidone, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01599">Probucol</a></td><td>Probucol decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Propafenone increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00339">Pyrazinamide</a></td><td>Pyrazinamide decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>The barbiturate, quinidine barbiturate, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>Synercid increases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>Cyclosporine may increase the therapeutic and adverse effects of repaglinide.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>The rifamycin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The rifamycin decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB06372">Rilonacept</a></td><td>results in increased immunosuppressive effects; increases the risk of infection. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>The protease inhibitor, ritonavir, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01098">Rosuvastatin</a></td><td>Cyclosporine may increase the serum concentration of rosuvastatin. Limit rosuvastatin dosing to 5 mg/day and monitor for changes in the therapeutic and adverse effects of rosuvastatin if cyclosporine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00778">Roxithromycin</a></td><td>The macrolide, roxithromycin, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>The protease inhibitor, saquinavir, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>The barbiturate, secobarbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00658">Sevelamer</a></td><td>Sevelamer decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Sibutramine increases the effect and toxicity of cyclosporine</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>Increases the effect and toxicity of sirolimus</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00359">Sulfadiazine</a></td><td>The sulfonamide decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01582">Sulfamethazine</a></td><td>The sulfonamide decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01015">Sulfamethoxazole</a></td><td>The sulfonamide decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00795">Sulfasalazine</a></td><td>The sulfonamide decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB01138">Sulfinpyrazone</a></td><td>Sulfinpyrazone decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>The NSAID, sulindac, may increase the nephrotoxic effect of cyclosporine. Sulindac may increase the serum concentration of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine levels and nephrotoxicity during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive renal impairment may occur during concomitant therapy with cyclosporine. Combination therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00306">Talbutal</a></td><td>The sulfonamide decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Cyclosporine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cyclosporine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of cyclosporine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of cyclosporine if telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00469">Tenoxicam</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may decrease the plasma concentration and therapeutic effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00894">Testolactone</a></td><td>The androgen, Testolactone, may increase the hepatotoxicity of Cyclosporine. Testolatone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity. </td></tr><tr><td><a href="/drugs/DB00624">Testosterone</a></td><td>The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity. </td></tr><tr><td><a href="/drugs/DB01420">Testosterone Propionate</a></td><td>The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>Thiopental may increase the metabolism and clearance of Cyclosporine. Monitor for changes in the therapeutic/adverse effects of Cyclosporine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>Tiaprofenic acid may increase the nephrotoxicity and/or the serum concentration of cyclosporine. Consider altnerate therapy or monitor for increased cyclosporine concentrations and nephrotoxicity during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine decreases the effect of cyclosporine</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may affect the efficacy/toxicity of Cyclosporine. </td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Cyclosporin (and other strong immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression and infection. It is recommended to avoid concurrent therapy. </td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Tolmetin may increase the serum concentration of cyclosporine and/or increase the nephrotoxicity of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine serum concentration and nephrotoxicity during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Cyclosporine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Cyclosporine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Cyclosporine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The ACE inhibitor, Trandolapril, may increase the nephrotoxicity of Cyclosporine. </td></tr><tr><td><a href="/drugs/DB05275">transdermal testosterone gel</a></td><td>The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Cyclosporine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cyclosporine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00197">Troglitazone</a></td><td>Troglitazone decreases the effect of the immunosuppressant</td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>The macrolide, troleandomycin, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01586">Ursodeoxycholic acid</a></td><td>Ursodiol increases the levels of cyclosporine</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil may increase the serum concentration of cyclosporine by inhibiting CYP3A4-mediated metabolism of cyclosporine. Monitor for changes in the therapeutic/adverse effects of cyclosporine if verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cyclosporine by decreasing its metabolism. Consider reducing the dose of cyclosporine. Monitor cyclosporine serum concentrations and therapeutic and toxic effects if initiating, discontinuing or adjusting voriconazole therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid salt substitutes containing potassium.</li>
<li>Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.</li>
<li>Red wine may reduce cyclosporine levels due to increased metabolism, therefore it appears prudent  to avoid red wine (white wine does not appear to affect cyclosporine metabolism).</li>
<li>When taken with a meal, AUC and Cmax of cyclosporine modified decreased.</li></ul></td></tr></tbody></table>